Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov
Jun Xu(Renmin University of China), Hua Xu(Tohoku University), Amber M. Johnson(The University of Texas MD Anderson Cancer Center), Liang‐Chin Huang(Dairy Management), Jia Zeng(The University of Texas MD Anderson Cancer Center), Trevor Cohen(University of Washington Medical Center), Elmer V. Bernstam(The University of Texas Health Science Center at Houston), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Vijaykumar Holla(The University of Texas MD Anderson Cancer Center), Yaoyun Zhang(Zimmer Biomet (Netherlands)), Yonghui Wu(Guangdong University of Foreign Studies), Hee-Jin Lee(The University of Texas Health Science Center at Houston), Ann M. Bailey(The University of Texas MD Anderson Cancer Center)
Cited by 24
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
A large language model for electronic health records
|npj Digital Medicine|2022|805
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530